BMO Capital Starts Ambit Biosciences (AMBI) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Leerink Swann Starts Ambit Biosciences (AMBI) at Outperform
June 10, 2013 7:51 AM EDTLeerink Swann initiated coverage on Ambit Biosciences (NASDAQ: AMBI) with an Outperform rating and a price target of $14.00.
Analyst Howard Liang said, "In an area where chemotherapy remains as the standard of care with limited breakthrough, we see AMBI's quizartinib as the best-in-class FLT3... More
Citi Starts Ambit Biosciences (AMBI) at Buy
June 10, 2013 7:08 AM EDTCiti initiates coverage on Ambit Biosciences (NASDAQ: AMBI) with a Buy. PT $13.00.
For an analyst ratings summary and ratings history on Ambit Biosciences click here. For more ratings news on Ambit Biosciences click here.
Shares of Ambit Biosciences closed at $7.79 yesterday, with a 52 week range of $6.22-$8.24.... More
